Fig. 2

The clinical significance of MCM3AP-AS1 in HCC. a Based on TCGA data from R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl), the expression of MCM3AP-AS1 in 232 cases of HCC with low tumor grades (G1-G2) and 134 samples of HCC with high tumor grades (G3-G4). P = 0.0032 by Student’s t-test. b The expression of MCM3AP-AS1 in 258 cases of HCC with early tumor stages (I-II) and 91samples of HCC with advanced tumor stages (III-IV). P = 0.0013 by Student’s t-test. c Kaplan-Meier survival analysis revealed that HCC patients with high MCM3AP-AS1 expression showed a significant poorer overall survival compared to those with low MCM3AP-AS1 expression. The median expression level of MCM3AP-AS1 was used as the cut-off. P = 0.0054 by Log-rank test. d TCGA data from OncoLnc (http://www.oncolnc.org/) further demonstrated that high MCM3AP-AS1 expression also indicated poor survival of HCC patients. The median expression level of MCM3AP-AS1 was used as the cut-off. P = 0.0112 by Log-rank test